Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR in Non-Functioning Pituitary Adenoma
NCT01283542Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Primary completion
- Sep 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in non-functioning pituitary adenoma (NFPA), sponsored by Novartis. Started Nov 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
non-functioning pituitary adenoma (NFPA)
Beyond the preview
Go deeper on NCT01283542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283542.